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ABSTRACT
Cyclin dependent kinase (Cdk)9 acts through the positive
transcription elongation factor-b (P-TEFb) complex to activate and
expand transcription through RNA polymerase II. It has also been
shown to regulate cardiomyocyte hypertrophy, with recent evidence
linking it to cardiomyocyte proliferation. We hypothesised that
modification of CDK9 activity could both impair and enhance the
cardiac response to injury by modifying cardiomyocyte proliferation.
Cdk9 expression and activity were inhibited in the zebrafish (Danio
rerio) embryo.We show that dephosphorylation of residueSer2 on the
C-terminal domain of RNA polymerase II is associated with impaired
cardiac structure and function, and cardiomyocyte proliferation and
also results in impaired functional recovery following cardiac laser
injury. In contrast, de-repression of Cdk9 activity, through knockdown
of La-related protein (Larp7) increases phosphorylation of Ser2 in
RNA polymerase II and increases cardiomyocyte proliferation. Larp7
knockdown rescued the structural and functional phenotype
associated with knockdown of Cdk9. The balance of Cdk9 and
Larp7 plays a key role in cardiomyocyte proliferation and response to
injury. Larp7 represents a potentially novel therapeutic target to
promote cardiomyocyte proliferation and recovery from injury.
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INTRODUCTION
Cyclin dependent kinase 9 (CDK9) has emerged from the wider
family of CDKs as an important signaling mechanism in the
initiation and progression of cardiac hypertrophy (Krystof et al.,
2012, 2010). Sano and colleagues (2002) have shown that CDK9
expression is upregulated and activity is enhanced during cardiac
hypertrophy, and that chronic activation of CDK9 predisposes to
heart failure in adult mouse myocardium. More recently, CDK9 has
been shown to act as a binding partner of GATA4, an important
regulator of cardiomyocyte proliferation in mammals and zebrafish
(Kikuchi et al., 2010). This link to GATA4 provides support for a
possible role of CDK9 in regulating cardiomyocyte proliferation
(Sunagawa et al., 2010).
In mammalian species, cardiomyocytes proliferate rapidly during
fetal life but lose this capacity within the weeks and months
following birth, leaving only a very low level of background mitosis
in adult hearts (Ahuja et al., 2007). The zebrafish heart, by contrast,
retains a much higher rate of background cardiomyocyte cell
division throughout adulthood, which is associated with a
remarkable capacity to regenerate cardiac tissue following injury
(Poss et al., 2002). An additional contrasting feature of the zebrafish
heart is that, unlike the mammalian heart, it appears to lack a classic
hypertrophic response, although few hypertrophic models have
been developed in the fish (Sun et al., 2009). Indeed, Becker and
colleagues (2011) have shown that a Troponin T (tnnt2) gene
knockdown targeting the exon 13 splice donor site in embryonic
zebrafish, designed to mimic human hypertrophic cardiomyopathy,
results in cardiomyocyte hyperplasia and a dilated ventricle, despite
a switch in the use of molecular pathways associated with
hypertrophy.
Cardiac hypertrophy is typically associated with a global increase
in mRNA and protein synthesis in cardiomyocytes. CDKs are a
family of cell cycle regulators that are closely linked to transcription
(Garriga and Grana, 2004; Loyer et al., 2005). Indeed, persistent
endogenous CDK inhibition in adult cardiomyocytes has been
proposed as one of the reasons why these cells rarely re-enter the cell
cycle following injury or in response to haemodynamic, or other,
stress. In support of this, knockdown of endogenous CDK inhibitors
by using small interfering RNA induces neonatal and adult
cardiomyocytes to re-enter the cell cycle, resulting in active
proliferation of previously quiescent cells (Di Stefano et al.,
2011). This intriguing finding suggests that there is a key role for
CDKs in controlling the proliferative behaviour of cardiomyocytes
and points to a potential mechanism by which cardiomyocytes
could be induced to divide.
CDK9 becomes active by complexing with cyclin T, forming the
positive transcription elongation factor b (P-TEFb), leading to
enhanced transcriptional activity through RNA polymerase II.
Inactivation results from binding to hexamethylene-bisacetamide-
induced protein (HEXIM) 1 and/or HEXIM2 (Barboric et al., 2005;
Yik et al., 2003) and the La-related protein 7 (LARP7) (He et al.,
2008; Markert et al., 2008). LARP7, also called PIP7S (He et al.,
2008), is a highly specialised RNA-binding molecule that stabilises
the CDK9 inactivating complex by providing a bridge between
7SK-RNA and HEXIM proteins. Indeed, a previous study (Markert
et al., 2008) using silencing-RNA against LARP7 caused
upregulation of RNA polymerase II activity. LARP7 therefore
appears to be an important regulator of CDK9 and consequently of
P-TEFb complex activity (Krueger et al., 2008).
These regulatory mechanisms provide novel and important
insights into ways in which CDK9 could be manipulated for
therapeutic benefit. Indeed, although pharmacological CDK9
inhibition has been proposed as a therapy for abrogating cardiac
hypertrophy (Krystof et al., 2010), the possibility of enhancing
CDK9 activity has been overlooked as a mechanism that could be
used to induce cardiac hypertrophy and to stimulate cardiomyocyteReceived 28 May 2015; Accepted 29 October 2015
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proliferation. CDK9 is therefore a potentially important pathway
that merits further evaluation as a therapeutic target.
In this study, we modulated Cdk9, both genetically and
pharmacologically, in the zebrafish embryo. We show that genetic
knockdown and pharmacological inhibition of Cdk9 inhibits
cardiomyocyte proliferation, and reduces cardiac function and the
ability of the heart to recover following cardiac laser injury.
Conversely, genetic inhibition of Larp7, a Cdk9 repressor, provoked
both a hyperplastic and hypertrophic cardiac response with
preservation of cardiac function following injury, and rescued the
effects of CDK9 knockdown.
RESULTS
Cdk9andLarp7 expression displaydistinct patterns inwhole
larvae and in isolated larval hearts during normal
development
Cdk9 was detected in normal whole larvae from 24 h post
fertilisation (hpf ) and showed a distinctive pattern of expression
during the course of development, increasing between 24 and
72 hpf (P<0.01) and then decreasing towards 120 hpf (Fig. 1A). In
pooled isolated embryonic hearts (n=150 per sample, n=3
samples), Cdk9 mRNA peaked at 48 hpf and again at 96 hpf,
decreasing at 120 hpf to levels then detected in adult isolated
hearts. Cdk9 was also detectable at moderate levels (relative to
those in the embryo) in the adult heart (Fig. 1B). In whole larvae,
Larp7 expression reached a peak at 48 hpf and then decreased at
72, 96 and 120 hpf (Fig. 1C). In isolated embryonic hearts, Larp7
mRNA levels increased slightly between 48 and 96 hpf, and then
reduced at 120 hpf. In the adult heart, Larp7 mRNA was also
detectable (Fig. 1D).
Survival and gross phenotype of flavopiridol- and Cdk9-
morpholino-treated larvae
Incubation of embryos in flavopiridol at less than 24 hpf resulted in
high levels of mortality, and so we used continuous incubation from
24 hpf, which resulted in a modest reduction in survival in treated
embryos compared to that of controls at 120 hpf (77±3% vs 91±4%,
respectively, P>0.05; Fig. S1A).
Absence of heart beat and lack of tail blood flow combined with
other major structural malformations were the criteria used to
evaluate mortality. These larvae also displayed an excess of body
axis deformities, a small head, pericardial oedema and reduced
tail blood flow. Flavopiridol had no significant effects on the
anatomical configuration of the heart.
Treatment with a morpholino that blocked the ATG translation of
cdk9 (Cdk9-Mo-TB) resulted in a significant reduction in survival
compared to that of controls at 120 hpf (47±4.5% vs 85±4%,
respectively, P<0.001; Fig. S1B). In contrast, treatment with a
morpholino that blocked the splicing of cdk9 (Cdk9-Mo-SB) was
associated with a higher level of survival compared to that of
controls (72±5% vs 85±4%, respectively, P>0.05). Larvae that had
been treated with the morpholinos against cdk9 displayed an excess
of developmental and structural abnormalities, compared to
controls, including deformity of trunk and tail curvature, a small
head, pericardial oedema, reduced tail blood flow and global
developmental delay compared with controls (Fig. S2). These
abnormalities were less frequent upon treatment with Cdk9-Mo-SB
compared to treatment with Cdk9-Mo-TB. This is a fairly typical
observation because translation-blocking morpholinos are known to
inhibit both maternal and zygotic transcripts (Nasevicius and Ekker,
2000), whereas splicing-blocking morpholinos act only on zygotic
transcripts. Owing to the high mortality associated with the Cdk9-
Mo-TB, we preferentially used embryos that had been treated with
Cdk9-Mo-SB, which showed a similar degree of Cdk9 protein
knockdown, during the majority of the laser injury and rescue
experiments to avoid the confounding issue of selection-survival bias.
Effects of Cdk9 inhibition on cdk9 gene transcription, protein
expressionandphosphorylationofSer2onRNApolymerase II
Treatment with flavopiridol caused a reduction in the levels of
the phosphorylated form of the serine 2 residue of the C-terminal
domain in whole larvae compared to that in controls (Fig. 2A–C), as
Fig. 1. qPCR assessment of cdk9 and larp7
gene expression in thewhole embryo and in
isolated zebrafish hearts. cdk9 and larp7
mRNA relative abundance in whole embryos
collected between 24 and 120 hpf (A,C), and in
isolated embryonic hearts at 48, 96, 120 hpf, as
well as in adult heart (6 months of age) (B,D).
Data were compared using one-way ANOVA
followed by Bonferroni’s multiple comparison
test. Each time-course was studied in one
clutch of eggs with at least 10 embryos per time
point. Mean values represent three clutches of
eggs. Error bars represent s.e.m.
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predicted because of its known pharmacological action (Chao et al.,
2000; Bosken et al., 2014). However, flavopiridol-treated embryos,
unexpectedly, showed an increase in Cdk9 protein in whole larvae at
72 and 96 hpf (Fig. 2B,C).
Larvae that had been injected with Cdk9-Mo-SB showed a
marked reduction in the abundance of cdk9mRNA by over 70%, as
expected with morpholino treatment (Fig. 2D). This resulted in
about a 20% reduction in the levels of Cdk9 protein at 48 and 96 hpf
(Fig. 2E,F). This reduction in Cdk9 protein was confirmedwith both
splice- and translation-blocking morpholinos (Fig. 2F).
Cdk9 inhibition reduces size and function of the ventricle
During normal development, zebrafish larvae show a progressive
increase in ventricle size, measured as diastolic area, in the period
72–120 hpf. The ejection fraction of the ventricle does not change
during normal development. However, the increase in heart rate and
cardiac size results in an increase in cardiac output. Pharmacological
inhibition of Cdk9 with flavopiridol from 24 hpf onwards reduced
ventricle size and the ejection fraction compared to controls
(Fig. 3A), although flavopiridol did not have a great impact on the
anatomical structure of the heart (Fig. 3C). Treatment with Cdk9-
Mo-SB had amarked effect on cardiac structure during development
with a high proportion of hearts showing a string-like appearance at
120 hpf (Fig. 3B,C). These hearts were also significantly smaller
and displayed a reduced ejection fraction (Fig. 3B).
Larp7 knockdown causes a mild cardiac phenotype with
enhanced phosphorylation of Ser2 on RNA polymerase II
Larvae that had been injected with a morpholino blocking Larp7
splicing or translation (Larp7-Mo-SB and Larp7-Mo-TB,
respectively) displayed similar rates of survival at 120 hpf to
Larp7-mismatch-injected controls (90%) (Fig. S1C) with mild
structural and cardiac abnormalities (see Fig. 4A; Fig. S3). Ventricle
diastolic area and the ejection fraction were not different between
the two groups (Fig. 4B,C), whereas atrial diastolic area was
significantly greater in the hearts of embryos that had been injected
with the Larp7 morpholinos compared to controls (Fig. 4D). Larp7-
Mo-SB-injected larvae had a significant reduction in larp7 mRNA
by approximately 40% (Fig. 4E) and a reduction in Larp7 protein by
70% (Fig. 4E,F) compared to controls. Larp7-Mo-TB-injected
larvae showed an increase in phosphorylation of Ser2 on RNA
polymerase II compared to mismatch-treated controls (Fig. 4F),
consistent with activation of Cdk9.
Effects of Cdk9 modulation on cardiomyocyte proliferation
The total number of ventricle cardiomyocytes (VCt) increased
progressively during development in controls. Larvae that had been
exposed to flavopiridol 3 µmol/l (Fig. 5A) showed reduced VCt
during this same developmental time period. Larvae that had been
treated with Cdk9-Mo-SB also showed significantly lower VCt
compared to mismatch controls with a reduction of 25%, 48% and
Fig. 2. Effect of Cdk9 inhibition on Cdk9 levels and phosphorylation of RNA polymerase II at Ser2. Effects of flavopiridol (A–C) on the downstream
phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II [P-Ser2 (CTD)] (A) and onCdk9 protein expression at 48, 72 and 96 hpf (B). Lower panels
show sample western blot membranes after Flavopiridol (C) and Cdk9-Mo (F) treatment showing Cdk9 isoform 55 kDa (CDK955), which is dominant over the
expression of the smaller isoform at 42 kDa (CDK942) Cdk9 mRNA (D) and protein (E) levels were significantly reduced at 48 and 96 hpf following injection of
Cdk9-Mo-SB or Cdk0-Mo-TB. β-actin mRNA was used to normalise mRNA levels, whereas tubulin was used to normalise protein level. (n=3 experiments, >10
embryos per group, **P<0.01, ***P<0.001, one-way ANOVA test followed by Bonferroni’s post-hoc test). C, control; Fl, flavopiridol; Mism-Mo, mismatch
morpholino; Cdk9-Mo-SB, CDK9 morpholino splice blocking; Cdk9-Mo-TB, Cdk9 morpholino translation blocking. Means±s.e.m. are shown in A, B, D and E.
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70%, respectively, at 72, 96 and 120 hpf (Fig. 5B). We ensured that
only dividing cardiomyocytes were included in the counting process
by carefully confirming that each phospho-Histone-H3 (PHH3)-
positive nucleus colocalised with the DAPI and GFP signals.
Exposure to flavopiridol 3 µmol/l significantly reduced the number
of mitotic cardiomyocytes (Fig. 5D,E). The ratio of mitotic:total
cardiomyocytes at 72 hpf was 2.8% in flavopiridol-treated embryos
compared to 5.5% in controls, corresponding to a 55% reduction in
the number of PHH3-positive nuclei. In contrast, Larp7-Mo-
injected embryos (SB) showed an increased VCt at 120 hpf
compared to mismatch-injected controls (Fig. 5C).
Cdk9 modulation modifies GATA-family mRNA abundance in
whole larvae
Whole larvae (48 hpf) that had been incubated in flavopiridol
showed a reduction in the mRNA levels of gata4 by 48 hpf with no
change in the levels of gata5 and gata6 at this developmental stage
(Fig. 6A). However, at 96 hpf, larvae that had been treated with
flavopiridol showed an increased level of all GATA-family mRNA,
with values of 1.5±0.2 for gata4, 1.4±0.18 for gata5 and 1.49±0.3
for gata6 (mean±s.e.m.).
Larvae that had been treated with Cdk9-Mo-SB did not show a
difference in gata4 and gata5 at 48 and 96 hpf (Fig. 6B), whereas
there was a reduction in gata6 mRNA abundance at 96 hpf. Larvae
that had been treated with Larp7-Mo-TB showed no significant
changes in the abundance of mRNA levels for gata4, gata5 and
gata6 at 48 or 96 hpf (Fig. 6C).
Cdk9 inhibition impairs recovery from cardiac laser injury
In control larvae, laser injury of the ventricle at 72 hpf resulted in a
significant reduction in the ejection fraction and VCt at 2 h post
laser treatment (Fig. 7). By 24 h post laser treatment, both
parameters recovered to baseline levels that were comparable to
those before laser injury.
Larvae that had been exposed to flavopiridol or injected with
Cdk9-Mo-SB also showed a reduction in the ejection fraction and
VCt at 2 h post laser treatment; however, both parameters failed to
recover to control levels at 24 h post laser treatment (Fig. 7).
Larvae that had been treated with Larp7-Mo-TB showed a
significant reduction in the ejection fraction and VCt values at 2 h
post laser treatment with recovery to control levels at 24 h after laser
exposure (Fig. 7).
Co-injection of Larp7 morpholino and cdk9 capped RNA
attenuates the morphological phenotype in Cdk9-Mo-SB-
treated larvae, and restores functional recovery of the
ventricle following laser injury
Co-injection of larvae with Cdk9-Mo-SB and Larp7-Mo-SB
significantly attenuated the morphological abnormalities observed
with Cdk9-Mo-SB alone, with fewer embryos displaying body axis
and cardiac abnormalities (Fig. 8A–C). Co-injection of Cdk9-Mo-
SB and cdk9 RNA also significantly rescued the morphological
phenotype observed with Cdk9-Mo-SB alone (Fig. 8A–C). There
were significantly fewer larvae with small heads, curved tails,
string-like hearts and with a lack of tail blood flow. Although
the rescue with cdk9 capped RNA did not completely restore the
phenotype to normal, we observed a substantial improvement in the
structural and functional cardiac phenotype (Fig. 8C).
Following laser injury, co-injection of Cdk9-Mo-SB with either
cdk9 mRNA (capped) or Larp7-Mo-SB both enhanced recovery
from laser injury, with the ejection fraction restored to normal in
both co-injected embryo sets within 24 h (Fig. 8D). This
Fig. 3. Effects of CDK9 inhibition or knockdown on the structure and function of the developing zebrafish heart. For pharmacological inhibition (A), embryos
were continuously exposed to vehicle (1% DMSO, clear bars) or flavopiridol (3 μmol/l, dark bars) from 24 to 120 hpf. For morpholino-mediated knockdown (B),
embryo eggs at the one- to two-cell stage were injected with Cdk9 mismatch morpholino (clear bars) or Cdk9-targeting morpholino (SB, black bars). Ventricle ejection
fraction (A,B, upper panels) and diastolic area (A,B, lower panels) were assessed sequentially in the same embryos at 72, 96 and 120 hpf. Images inC showembryonic
hearts following treatment with flavopiridol and Cdk9-Mo (SB). Left-hand panels are bright field images of the heart, and right-hand panels are histological sections
through the heart stainedwith haematoxylin and eosin (H&E). n=3 experiments, >10 embryos per experiment, *P<0.05, **P<0.01, ***P<0.001. Two-wayANOVA test for
repeatedmeasures followedbyBonferroni’spost-hoc test. ‘A’, atrium;BA,bulbousarteriosus;V, ventricle.Means±s.e.m.areshown inupperand lowerpanelsofAandB.
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compared favourably with the larvae that had been injected with
Cdk9-Mo-SB alone, which showed a persistently depressed
ejection fraction at 24 h after laser injury.
DISCUSSION
The zebrafish embryo provides a unique opportunity to assess the
role of Cdk9 in cardiomyocyte proliferation by using a highly
accurate method of counting cardiomyocytes in whole embryonic
ventricles combined with detailed structural and functional
assessment of hearts at baseline and after laser-induced injury.
We provide evidence that Cdk9 plays a key role in early cardiac
development and in cardiomyocyte proliferation. We have shown
that Cdk9 action can be pharmacologically inhibited, resulting
in dephosphorylation of its target site on the C-terminal domain
of RNA polymerase II. Knockdown of cdk9 transcription by
using morpholino technology also resulted in reduced Cdk9
protein expression, leading to reduced phosphorylation of its target
site. We have shown that even a modest reduction (about 20%)
of Cdk9 protein, insufficient to cause significant structural or
developmental abnormalities, has a striking effect on the
embryonic heart, resulting in reduced size and function, and a
reduced capacity to recover from injury. In contrast, enhancing
Cdk9 activity through knockdown of its repressor molecule, Larp7,
increased cardiomyocyte proliferation and was associated with
normal recovery of the ventricle from laser injury. These findings
highlight the importance of Cdk9 in the developing heart and its
response to injury. Therefore, Cdk9 represents a fundamental
cellular mechanism in the heart that controls transcription and
proliferation, and point to its potential importance as a therapeutic
target.
Molecular pathways that are linked to CDK9 appear to be more
strongly associated with cell growth than control of cell cycle, where
other members of the CDK family have greater influence. Previous
work has demonstrated that a dominant-negative CDK9 construct
blocks ET-1-induced hypertrophy in cultured mouse
cardiomyocytes (Sano et al., 2002), confirming a key role for the
protein in cardiac hypertrophy.
CDK9 during embryonic development
In the mouse, cardiac CDK9 activity is highest during
embryonic stage (E)16.5, falling by 50% in the neonate and
further still to around 15% of that in the embryo by early
adulthood (Sano et al., 2002). In the zebrafish heart, quantitative
(q)PCR analysis indicates that Cdk9 is most strongly expressed
during the first 96 hpf of development, consistent with active
cardiomyocyte proliferation. Thereafter, mRNA levels fall only
modestly, by around 30%, remaining at around 70% of
embryonic expression levels into adult life. This apparent
difference could reflect the higher level of cardiomyocyte cell
turnover in the zebrafish heart compared with that in the mouse
(Soonpaa and Field, 1998).
Although the mechanisms of cell cycle regulation are broadly
conserved, the existence and function of Cdk9 in the zebrafish has
not been well described. One of the key aspects of our study was
Fig. 4. Effects of Larp7 knockdown on cardiac structure and function. (A) Larp7-targeting morpholinos [either splice blocking (SB) or translation blocking
(TB)] resulted in normal heart development, here shown in vivo (left hand panel) and following H&E staining (right hand panel). Ventricular diastolic area (B) and
ejection fraction (C) in Larp7-knockdown embryos were similar to controls (Larp7 mismatchmorpholino). Amild dilatation of the atrium (D) was observed in Larp7-
knockdown (TB and SB Larp7-Mo) embryos. Larp7 mRNA (E) and protein (F) were significantly reduced at 48 and 96 hpf. Larp7-Mo-TB (larp7 Mo) injection
caused increased phosphorylation of Ser2 in the RNA polymerase II C-terminal domain (P-Ser2 CTD), suggesting an upregulation of Cdk9 activity. n=3
experiments, *P<0.05, **P<0.01, ***P<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test. Means±s.e.m. are shown in B, C, D and E.
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to establish that Cdk9 is present and functional in the larval heart,
and to characterise its role in normal development. Inhibition of
Cdk9 by using flavopiridol produced a significant decrease in Cdk9
activity, as assessed by examining the phosphorylation of its target
site Ser2 on RNA polymerase II. Injection of cdk9-targeting
morpholinos also resulted in reduced Cdk9 expression. These
findings confirmed that Cdk9 is involved in the same pathway in the
zebrafish as it is in mammalian systems (Nguyen et al., 2001).
Treatment with morpholinos targeting cdk9 produced a number of
phenotypic traits that were generally more severe than those
observed with flavopiridol treatment, possibly reflecting differences
in the time points at which the two forms of treatment were applied
during development. Cardiovascular function was affected in both
cases, with a reduction in cardiomyocyte proliferation, ventricle
ejection fraction and tail blood flow.
Inhibition of CDK9
CDK9 inhibition is currently being evaluated in pre-clinical and
clinical studies for the treatment of a number of different cancers,
mainly in combination with other chemotherapeutic agents
(Hofmeister et al., 2014; Karp et al., 2010). Although it has been
proposed as a treatment for severe cardiac hypertrophy, there are no
published trials and no evidence of any ongoing trials of its use in
this clinical setting. The proposed mode of therapeutic action of
CDK9 inhibitors in cardiac hypertrophy is inhibition of RNA and
protein synthesis by limiting gene transcription.
In our study, flavopiridol initially caused a marked reduction in
the phosphorylation of its target site on the C-terminal domain of
RNA polymerase II (Fig. 2A,C). This effect was relatively transient,
despite continuous exposure to the drug, with normalisation of
phosphorylation levels at 96 hpf. Simultaneously, there was an
unexpected and progressive increase in the levels of Cdk9 protein
between 48 and 96 hpf, despite ongoing exposure to the drug
(Fig. 2B,C). The lack of specific antibodies for the total levels of
zebrafish RNA polymerase II did not allow us to fully exclude the
possibility that the levels of RNA polymerase II also changed under
our experimental conditions. Following flavopiridol treatment, we
observed a small non-significant rise in cdk9 mRNA abundance at
96 hpf. Taken together, these findings suggest that the initial effect
of flavopiridol changed with time, possibly owing to tolerance or
desensitisation, or to the use of alternative or redundant Cdk
pathways that lead to phosphorylation of the target site. The increase
in Cdk9 protein levels is interesting and could be the result of
a feedback mechanism that ensures ongoing and adequate
phosphorylation of the C-terminal domain of RNA polymerase II
to maintain RNA transcription and elongation. Postulating such a
mechanism is not unreasonable given the fundamental importance
of this pathway to basic cellular function. To our knowledge this is
the first evidence of a feedback mechanism linking Cdk9 and its
phosphorylation target site on RNA polymerase II.
Flavopiridol also reduced the mRNA abundance of gata4 in the
early stages of development and then later, towards 96 hpf, it
Fig. 5. Effects of Cdk9 modulation on ventricle cardiomyocyte proliferation during early development of the zebrafish heart. Effects of flavopiridol
(A, white bars, controls; black bars, flavopiridol 3 μmol/l) on the total number of cardiomyocytes in the isolated embryonic zebrafish ventricle. Effects of Cdk9
morpholino (B, Cdk9-Mo-SB, Cdk-Mo) and Larp7 morpholino (C, Larp7-Mo-SB, Larp7-Mo) on total cardiomyocyte number in the embryonic ventricle (white bars,
controls, appropriate mismatch morpholino; dark bars, splice-blocking morpholino. Effects of flavopiridol on the number of proliferating cardiomyocytes (D, white
bars, controls; black bars, flavopiridol 3 μmol/l). Representative confocal images (E) of isolated embryonic myl7:GFP hearts stained with DAPI (blue) and for
phospho-Histone-H3 (PHH3, red nuclei, marking proliferating cardiomyocytes). Data are mean±s.e.m., n=3 experiments, n=5 hearts per group, *P<0.05,
**P<0.01 ***P<0.001, two-way ANOVA test. Means±s.e.m. are shown in A, B, C and D.
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produced an increase in the whole GATA family, including gata4,
gata5 and gata6. This finding is somewhat counter-intuitive
because these transcription factors are widely recognised as
drivers of cardiomyocyte proliferation, which was also observed
to be adversely affected by flavopiridol. gata4, in particular, plays a
key role in a number of signaling pathways in the heart and is known
to be activated following haemodynamic stress (Cappola, 2008). Of
specific interest is the fact that gata4 has been shown to form a
complex with CDK9, promoted by the intrinsic histone acetyl-
transferase p300 that is also required for the kinase activity of
CDK9. This complex is, in turn, required for transcription-pathway
activation during cardiomyocyte hypertrophy (Sunagawa et al.,
2010). Despite the increasing levels of gata4, gata5 and gata6 at
96 hpf, cardiomyocyte proliferation did not increase significantly.
One possible explanation is that these three transcription factors
play a dominant role in cardiomyocyte proliferation in the very early
stages of heart development (6–24 h), whereas later in development
(24–48 h), other factors are more important in orchestrating the
proliferative process.
Enhancing CDK9 activity
Larp7 specifically binds to and enhances the stability of the complex
7SK-snRNA–HEXIM–CDK9, leading to repression of its action on
RNA polymerase II. Knockdown of Larp7 would be expected to
destabilise this complex, leading to an increase in CDK9 activity.
In contrast to CDK9 inhibition (either with flavopiridiol or direct
cdk9-targeted morpholino knockdown), Larp7 knockdown
provoked an increase in VCt that was not associated with an
increase in the ventricle size. This suggests a predominantly
hyperplastic response. There was no change in the ejection fraction
of the ventricle, although we did observe a consistent increase in
dimensions of the atrium. The cause for this is not clear, and a
contribution resulting from altered ventricular chamber stiffness
could have played a role.
Response to laser injury
Cardiac injury is widely recognised to cause a switch of specific
genetic and epigenetic programs (Bergmann and Steller, 2010;
Dilworth and Blais, 2011; King and Newmark, 2012; Monaghan
et al., 2012; Wang et al., 2012), which also occur in zebrafish (Kizil
et al., 2012). The model used here, involving targeted laser
treatment of the embryonic ventricle, has similarities to myocardial
infarction models in mammals – i.e. it generates a sudden loss of
myocardial tissue in a regional distribution. It is highly reproducible
and permits the study of both injury and recovery in a very short time
period of 24 h. At 2 h after laser injury, there is markedly reduced
cardiac function, accompanied by a reduced number of
cardiomyocytes and increased apoptosis in the area of injury
Fig. 6. PatternofexpressionofGATA-familygenes inwholeembryosat48and 96 hpf after treatmentwith flavopiridolormorpholino-mediatedknockdown.
For pharmacological inhibition (A), embryos were continuously exposed to vehicle (1% DMSO, white bars) or flavopiridol (3 μmol/l, dark bars) from 24 to 120 hpf.
For Cdk9 (B, Cdk9-Mo-SB) or Larp7 (C, Larp7-Mo-SB and -TB) morpholino-mediated knockdown embryos at the one- to two-cell stage were injected with the
appropriatemismatchmorpholino (white bars) or gene-targetingmorpholino (black bars).mRNAwas extracted fromwhole embryos (at least 10 embryosper group) at
48 and 96 hpf. The relative abundance ofmRNA for gata4, gata5 and gata6wasassessed by using qPCRanalysis. mRNA levels were normalised to those for β-actin
in each case. n=3 experiments, *P<0.05, ***P<0.001, two-way ANOVA followed by Bonferroni’s post-hoc test. Means±s.e.m. are shown in each figure.
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(Matrone et al., 2013). This functional loss recovers fully within
24 h. Inhibition of Cdk9 activity, with either flavopiridol or
morpholinos, resulted in a reduced capacity of the ventricle to
recover from injury. This failure to recover was associated with
diminished cardiomyocyte proliferation. Although loss of CDK9
action might have influenced a wide range of gene transcription
pathways, including apoptosis pathways (Sano et al., 2004), the
observed persistent cardiac dysfunction could have been greatly
affected by the observed reduction in cardiomyocyte proliferation.
Because Cdk9 knockdown caused a persistent reduction in the
expression of gata4, gata5 and gata6, which are recognised
proliferative transcription factors in the heart, we hypothesised
that Larp7 knockdown would increase the number of
cardiomyocytes. We also hypothesised that this approach would
enhance the ability of the ventricle to recover from injury. We
showed very clearly that the ventricles of Larp7-Mo-treated
embryos had increased numbers of cardiomyocytes at 120 hpf.
Subsequently, we showed that we could rescue the CDK9-Mo-SB
baseline phenotype with both cdk9 RNA and also by co-injecting
Larp7-Mo. We also showed that co-injection of Larp7-Mo reversed
the effects of CDK9-Mo-SB, permitting the embryonic heart to
retain its capacity to recover fully from laser injury. As part of a
set of validation experiments, we co-injected CDK9-targeting
morpholinowith the mismatch Larp7 morpholino. This co-injection
did not rescue the embryo phenotype. Only the co-injection of the
Cdk9- and Larp7-targeting morpholinos rescued the Cdk9-targeting
morpholino embryonic phenotype. In addition, we prepared the
solution immediately before the injection, to reduce as much as
possible the formation of non-specific complexes. However, we
cannot completely exclude the possibility of non-specific complex
formation interfering with the action of the Cdk9-Mo-SB. Larp7
knockdown alone did not significantly affect cardiac recovery from
laser injury.
The extent of Cdk9 protein knockdown resulting from
morpholino treatment was around 20%, indicating the persistent
availability of Cdk9 for modulation following Larp7-Mo
treatment. In addition, the dynamic sharing of Cdk9 between
the two complexes in which Cdk9 is involved – i.e. the Cdk9–
Cyclin active fraction and Cdk9–Larp7–Hexim–7SK inactive
fraction, represents a functional balance that can be perturbed.
Indeed, we believe that following Larp7 knockdown, more Cdk9
enzyme is released from the inactive complex leading to increased
activity. In mammals, the inactive P-TEFb complex includes
HEXIM and 7SK, and co-inhibiting two or more of these CDK9
repressors could be a possible short-term therapeutic approach to
enhance recovery from injury in the heart.
However, forcing mammalian cardiomyocytes to re-enter the cell
cycle could activate mechanisms controlling inappropriate cell
cycle entry in otherwise quiescent cells. For instance, a foreseeable
obstacle to this approach in cardiomyocytes is that E2F-1, which
provokes G1 exit and DNA synthesis (Kirshenbaum et al., 1996),
could also induce cardiomyocyte p53-dependent (Kowalik et al.,
1995) or -independent (Agah et al., 1997) apoptosis.
In this case, therapeutic interventions should include ad-hoc
modulation of anti-apoptotic genes, such as BCL-2 (Kirshenbaum
and de Moissac, 1997).
Clearly, further understanding of the factors and pathways
controlling CDK9 activity is required, and these pathways clearly
Fig. 7. Effects of Cdk9 modulation on the response of the ventricle to laser injury. Cdk9 activity was modulated pharmacologically and genetically by
incubation in 3 μmol/l flavopiridol and injection of Cdk9- and Larp7-targeting morpholinos (appropriate mismatch controls, grey bars; Cdk9-Mo-SB or Larp7-Mo-
SB, dark bars) prior to injury. Laser injury (single pulse to the mid-ventricular cavity) was performed at 72 hpf. Ejection fraction and cardiomyocyte number were
assessed pre-laser, and 2 and 24 h post-laser injury (n=3 experiments, n>10 embryos per experiment, two-way ANOVA test followed by Bonferroni’s post-hoc
test; *P<0.05, **P<0.01, ***P<0.001). Means±s.e.m. are shown in each figure.
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merit further study as possible therapeutic targets to address diseases
associated with acute and chronic heart injury.
Future perspectives
Our findings, although limited to the zebrafish embryonic heart, have
refocused on the importance of CDK9 as a potential therapeutic
target for human disease. There is clearly a need for further studies in
mammalian cardiac model systems. A first step would be to explore
CDK9 expression patterns in neonatal versus adult hearts and to
analyse its role in regenerative capacity (Porrello et al., 2011). It
would also be very important to understand whether a heart-specific
CDK9 isoform exists, which would permit development of drugs
targeted at the action of CDK9 in the heart, thus avoiding off-target
effects. De-repression of CDK9 through LARP7 knockdown or
inhibition is an intriguing approach, and one which could promote
cell survival and enhance proliferation. Although this could
potentially lead to carcinogenesis, short-term use during periods of
acute injury, such as after myocardial infarction, merit further study.
In conclusion, we have shown that the activity of CDK9 and
its repressor LARP7 can be modified to impact on cardiac growth
and development, specifically impacting on cardiomyocyte
proliferation. Short-term de-repression of CDK9 represents an
unexplored mechanism with the potential to promote functional
recovery of the heart following injury through a mechanism that is
associated with enhanced cardiomyocyte proliferation.
MATERIALS AND METHODS
Ethical approval
All experiments were approved by the local ethics committee and conducted
in accordance with the United Kingdom Animals (Scientific Procedures)
Act 1986 in an approved establishment.
Zebrafish maintenance
Zebrafish husbandry, embryo collection and maintenance were performed
according to accepted standard operating procedures (Nüsslein-Volhard
and Dahm, 2002). The cardiac myosin light chain 2:GFP transgenic line
[Tg(cmlc2:GFP)] (Burns et al., 2005) was used for all experiments; larvae
were maintained at 28.5°C on a 14-h-light–10-h-dark cycle and staged
according to Kimmel et al (1995). Larvaewere maintained in egg water until
dechorionated, and then in embryo medium (Westerfield, 2000). Embryos
were anaesthetised in a solution of Tricaine 20 µmol/l (ethyl 3-
aminobenzoate methanesulfonate, Sigma-Aldrich) or euthanised with an
overdose of the same compound. All experimental procedures were
performed at room temperature (23°C).
Morpholino injections
Suppression of Cdk9 and Larp7 expression was achieved using
antisense morpholinos (Gene Tools) designed against the splice donor
between exon 3 and intron 3, or targeting the mRNA AUG translational
start site.
Morpholino sequences were as follows: Cdk9-Mo-SB (accession number
NM_212591.1) 5′-CTTTCTTCCCCATTCTTTTACGTGG-3′; Cdk9-Mo-
TB 5′-CCTACGTCGCGCTGTTTTGGCCTTC-3′; Cdk9 control mismatch
5′-CTTTgTTgCCgATTgTTTTACcTGG-3′; Larp7-Mo-SB (accession
number NM_199930.1) 5′-TCATCTCCATACTAAACCAAACTGT-3′;
LARP7-Mo-TB 5′-TACTTTCACACAGTTGCGTTCTGCT-3′); Larp7
control mismatch 5′-TgATgTCCATAgTAAACgAAACTcT-3′. All
mismatch morpholinos represent protein-specific oligonucleotides where
mentioned in the text and figure legends.
0.5 nl of morpholino solution (100 µmol/l for Cdk9 and 200 µmol/l for
Larp7) was injected in one- to two-cell-stage larvae, just beneath the
blastoderm using a pulled glass pipette using a standard injector (IM300
Microinjector, Narishige, Japan). Successful injection was assessed under a
fluorescence microscope by using the red tag lissamine at the 3′ end of the
morpholino oligonucleotides.
Fig. 8. Rescue of the Cdk9-knockdown phenotype using capped cdk9 mRNA or Larp7-Mo-SB. (A–C) Survival and phenotype score in embryos treated
with CDK9-Mo-SB (Cdk9-Mo), LARP7-Mo-SB (Larp7-Mo), CDK9-Mo-SB+cdk9 mRNA, Cdk9-Mo-SB+Larp7-Mo-SB assessed independently during the first
120 hpf (n=3 experiments, n>50 embryos per group). (D) Effects of rescuing the Cdk9-knockdown phenotype (cdk9 mRNA or Larp7-Mo-SB) on recovery of the
cardiac function after laser injury (N=3, n=20–30 embryos per experiment). Two-way ANOVA and Bonferroni post-hoc test; ns, non-significant; *P<0.05, **P<0.01
and ***P<0.001. Means±s.e.m. are shown in B, C and D.
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Rescue of Cdk9 knockdown by cdk9mRNA
To determine whether the effect of the Cdk9-targeting morpholino was
specifically due to loss of Cdk9, we performed a rescue experiment by co-
injecting CDK9-Mo with capped cdk9 RNA. This capped RNA was
produced using an IMAGE clone encodingDanio rerio cdk9 cDNA (Source
Bioscience), which was sub-cloned into pNR-LIB (Source Bioscience).
Following linearisation with XhoI restriction enzyme (Applied Biosystems),
capped cdk9 RNA was transcribed using an mMessage mMachine Kit
(Ambion) according to the manufacturer’s instruction. A bolus of 1 nl of
solution containing CDK9-targeting morpholino at 100 µmol/l and 1.25 ng
of cdk9 RNA was injected into each egg.
Rescue of the effects of Cdk9 knockdown through Larp7
knockdown
Co-injection of Cdk9-Mo-SB and LARP7-Mo was performed to assess
whether the phenotype and the response to laser injury observed in Cdk9-
Mo-SB-treated larvae could be rescued by Larp7 knockdown. A bolus of
1 nl of solution containing Cdk9-targeting morpholino at 100 µmol/l and
Larp7-targeting morpholino 200 µmol/l was injected in each egg.
Pharmacological treatment of larvae
Flavopiridol is recognised as a potent ATP competitive kinase inhibitor for
CDK9 (Bosken et al., 2014; Baumli et al., 2008), that is now in clinical
trials (Wang and Fischer, 2008). Zebrafish larvae (24 hpf) were placed in
embryo medium containing flavopiridol 3 µmol/l (Sigma-Aldrich)
diluted in 1% DMSO. Solutions were replaced at 48, 72 and 96 hpf.
Control embryos were exposed to 1% DMSO. The drug concentration of
3 µmol/l was selected after a series of experiments assessing the
concentration of flavopiridol because it resulted in minimum toxicity to
the whole embryo while also resulting in a significant decrease in Cdk9
activity, confirmed by reduced phosphorylation of the residue Ser2 on
RNA polymerase II.
Assessment of ventricular function
Videos of the beating heart were captured by using a video camera (IonOptix
CCD100 MyoCam™, Dublin, Ireland), mounted on a microscope
(Axioscope II MOT Plus, Zeiss) linked to a computer. Ventricle end-
systolic and end-diastolic area were measured using image analysis software
(ImageJ). Fractional-area change (ejection fraction) was estimated by
subtracting ventricular systolic area from diastolic area, expressed as a
percentage of diastolic area, as previously described (Shu et al., 2003).
Histology and ventricle cardiomyocyte number
VCt and proliferating ventricular cardiomyocyte number, counted as DAPI-
and PHH3-positive nuclei, respectively, were assessed in whole-mount
isolated embryonic hearts, as previously described (Matrone et al., 2015).
Larvae were euthanised in 1 mM tricaine and fixed in 4% paraformaldehyde
(PFA, Sigma-Aldrich). Microdissected hearts were pre-incubated in
proteinase K (10 µg/ml) to allow permeabilisation, washed in PBS and
Triton-X100 (0.1%) and then blocked in bovine serum albumin 5% in PBS
for 3 h before being incubated with an anti-PHH3 antibody (Millipore
05-670; rabbit, 1:200), followed by incubation with anti-rabbit IgG antibody
(Alexa Fluor, Dako, 1:500). Subsequently, hearts were incubated in DAPI
(Sigma-Aldrich, 1:1000) for 1 h, washed in PBS and then mounted in
glycerol 100%. Confocal microscopy (Leica SP5) was used to capture
z-stack images of isolated heart ventricles at 3 µm intervals. The VCt and the
number of mitotic ventricular cardiomyocytes were counted using ImageJ
software, by marking each nucleus with a tag while moving progressively
through the z-stack. Only cardiomyocytes were included in the counting
process by ensuring that each nucleus was located within a GFP-positive
region of the heart. The atrium and bulbous arteriosus were excluded from
counting. Counting was performed by a single individual, blinded to the
original treatment of the heart. Intra-observer variation for a sample of 25
hearts was ±4.5%.
Haematoxylin and eosin (H&E) staining of whole larvae was performed.
Serial 4 μm sagittal sections were stained according to standard protocols
(Sabaliauskas et al., 2006).
Heart laser injury
Laser injury of the zebrafish embryonic heart was induced using a
XYclone laser (Hamilton-Thorne, USA), using a technique that has been
previously reported by our group (Matrone et al., 2013). The protocol for
laser injury and recovery is summarised in Fig. S4. Briefly, larvae at
72 hpf were anaesthetised using tricaine at 20 µmol/l (Sigma-Aldrich) and
placed on a plain glass microscope slide in a minimal amount of water.
Under standard white light microscopy (Axioscope II MOT Plus, Zeiss), a
laser pulse was delivered to the midpoint of the ventricle (see Movie 1).
The average energy delivered per pulse was 0.9 mJ over a duration of 3 ms
(300 mW), directed at an area approximately 10 μm in diameter. After
injury, each embryo was immediately placed into embryo medium to
recover for a further 48 h. Control larvae, kept in identical conditions and
manipulated in the same way, received laser injury to the distal tail-fin.
Gene expression
qPCR was used to assess the mRNA levels of cdk9, larp7, gata4, gata5 and
gata6, following morpholino injection or flavopiridol exposure.
RNA extraction and reverse transcription were performed by using
Qiagen RNeasy mini kit (Qiagen).
Larvae were placed in a 1.5-ml Eppendorf tube, euthanised with tricaine
overdose and stored in RNAlater (Life Technologies) or, for immediate
RNA extraction, placed directly in 600 µl of buffer RLT. Two small metallic
beads that had been previously autoclaved and wiped with RNase Zap (Life
Technologies) were added to each Eppendorf. Efficient disruption and
homogenisation was performed bymilling for 45 s at 30 Hz (MixerMill 301
model, Retsch, Haan, Germany) while keeping the larvae homogenate cold
at all times. Beads were removed, and the samples were centrifuged at
13,000 g for 3 min at 4°C. The supernatant was placed in a new 2-ml
Eppendorf tube, and the pellet was discarded. Supernatant was added with
an equal volume of 70% ethanol, mixed and placed in the RNeasy spin
column subjected to centrifugation (12,000 g, 30 s, 4°C). The eluate was
discarded.
The DNase treatment step was performed subsequently to eliminate
genomic DNA contamination. After wash with buffer RW1 (350 μl) and
centrifugation for 15 s, 10 μl DNase I stock solution, previously diluted in
70 μl of buffer RDD, were added to the spin column and incubated for
15 min at room temperature. The column was then washed with buffer RW1
(700 μl) and buffer RPE (500 μl). In each case, the eluate was discarded
following centrifugation (12,000 g, 15 s, 4°C). Buffer RPE (500 μl) was
added to wash the membrane, followed by a further centrifugation step
(12,000 g, 2 min, 4°C). The spin column was then placed in a fresh 2 ml
collecting tube and subjected to centrifugation (16,000 g, 1 min, 4°C) to
eliminate any buffer RPE carryover. The spin column was then placed in a
fresh 1.5-ml Eppendorf, RNase-free water (30 μl) was added, and the RNA
was eluted by using centrifugation (12,000 g, 1 min, 4°C). Eluted RNAwas
stored at −80°C.
RNA was quantified using a Nanodrop Spectrophotometer (Thermo
Fisher) in 1 μl of RNA sample. Concentration was determined by the
absorbance at 260 nm wavelength (A260), and the purity assessed by the
ratio of RNA/DNA (A260/A280), which was deemed acceptable if between
1.9 and 2.1, and a 260/230 ratio (some contaminants, e.g. phenol, absorb at
230 nm) >2.2.
Quality of RNA was assessed by electrophoresis on agarose (Lonza) gel
(1% w/v in 0.5× TBE). Samples (2 μl) were prepared by adding loading dye
(Promega) 1 in 5 diluted in distilled water. Samples were incubated at 85°C
for 3 min to denature RNA before running on the gel (100 V, 1 h) with a size
marker (New England Biolabs). RNA integrity was assessed on the basis of
18S and 28S ribosomal RNA (rRNA) bands. RNA integrity was deemed
satisfactory if clear 28S and 18S rRNA bands were present without
smearing, and if the 28S rRNA band was approximately twice as intense as
the 18S rRNA band.
RNA was reverse transcribed in cDNA by using high capacity cDNA
reverse transcription kit (Applied Biosystems).
For each sample, a volume containing 2 µg of RNA was pipetted into a
0.2 ml microfuge, and made up to 10 μl with nuclease free water, then 10 μl
of RT master mix (2×) was added. Two negative controls were prepared as
above, onewith water instead of RNA to identify any RNA contamination in
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the reagents, the second without the reverse transcriptase enzyme in order to
detect the presence of contamination by genomic DNA. Samples were
incubated (25°C, 10 min; 37°C, 120 min; 85°C, 5 min; 4°C, ∞) in a PCR
machine, before being chilled to 4°C. The resultant cDNA was stored at
−20°C.
To enable quantitation of gene expression, two housekeeping genes were
chosen based on their stability in respective experiments. Ef1α was used
during normal embryonic development, whereas β-actin was used during
embryonic exposure to flavopiridol or treatment with morpholinos.
Primers were designed to match probes within the Roche Universal Probe
Library (https://www.roche-applied-science.com). cDNA samples were
heated for initial denaturation (95°C, 5 min), then underwent 50 cycles of
PCR amplification, which comprised denaturation (95°C, 10 s), annealing
(60°C, 30 s) and elongation (72°C, 1 s). Upon completion of the PCR
program, samples were cooled (40°C, 30 s). For all the samples,
amplification curves were plotted (y-axis fluorescence, x-axis cycle
number). Triplicates were deemed acceptable if the standard deviation of
crossing point (Cp) was <0.5 cycles. Relative quantification was calculated
using the ΔCT method and Light Cycler software.
Protein analysis
Western blotting followed by densitometric quantification of the membrane
bands (ImageJ software) was used for semi-quantitative analysis of proteins.
Anti-Cdk9 antibody was produced in rabbit (C12F7, Cell Signaling
Technology; 1:200 in PBS); an antibody recognising RNA polymerase II
phosphorylated at Ser2 was produced in mice (ab24758, Abcam; 1:500 in
PBS); Larp7 was recognised using a synthetic peptide (AV40848, Sigma-
Aldrich; 1:1000 in PBS). To correct for variations in the amount of total
protein loaded onto the gel, the levels of target proteins were normalised to
those of protein β-tubulin (ab6046, Abcam).
Embryo chorion and yolk sac were surgically removed using fine forceps
(Dumont #5). Dechorionated and de-yolked larvae were transferred into
fresh, cooled PBS solution and rinsed twice, and transferred into a 1.5-ml
Eppendorf tube. Samples were microfuged for 1–2 min, and supernatant
was removed. About 100–150 μl RIPA lysis buffer (Millipore), that had
been previously diluted in deionised water from a 10× stock, was added and
homogenised with a microfuge pestle for 30 s, and then sonicated for 30 s at
5–8 μW, until the embryo sample was no longer visible. Samples were kept
in ice for 30 min, then were briefly vortexed and microfuged for 1–2 min.
Supernatant was collected and then placed in a new 1.5 ml tube, and the
pellet was discarded.
The protein concentrations of zebrafish larvae homogenates were
determined colorimetrically using a Bio-Rad protein assay kit (Bio-Rad)
and the Bradford method of detection.
An appropriate amount of protein sample containing 20 μg of total
protein was taken into a fresh Eppendorf tube, and 4 μl of 4× Laemmli buffer
and deionised water were added to make a final volume of 16 μl. Samples
were mixed and heated at 95°C for 5 min.
Samples were separated by electrophoresis on aNuPAGE®Novex® 4–12%
Bis-Tris gels, 1.0 mm thick (Life Technologies). In addition to the samples,
5 μl of Novex® Sharp Pre-stained Protein Standard (Life Technologies) was
also loaded to identify the molecular mass of bands. Gels were run at a voltage
100 V for 30 min and then at 150 V for another 60 min.
Gels were transferred onto nitrocellulose membranes Protran (Sigma-
Aldrich) using the Electrophoretic Transfer Cell (Bio-Rad Laboratories).
A gel sandwich was prepared within the cassette, comprising fibre pad,
blotting paper (both from Bio-Rad Laboratories), gel, nitrocellulose
membrane, filter paper and fibre pad. The gel sandwich cassette was
placed within the transfer module and tank, which was then filled with
Towbin transfer buffer (Tris-HCl 0.025 M, glycine 0.192 M, pH 8.6±0.1).
The transfer was run at 100 V and 300 mA for about 3 h at 4°C.
Nitrocellulose was then stained in Red Ponceau (Sigma-Aldrich) for
5 min and then washed in water to check for the presence of protein, and the
remaining gel was stained in Coomassie Blue R-250 0.5% (Bio-Rad
Laboratories) for 1 h, followed by several washes in decolouration solution
to assess that good transfer had occurred.
After transfer, nitrocellulose membrane was blocked with 20 ml of 5%
dried skimmed milk (Marvel Premier Brands, Lincolnshire, UK) in TBS
Tween [20 mM Tris-Cl (0.2 M Tris-Cl, pH 7.6), 137 mM sodium chloride,
0.1% Tween 20 (Polyoxyethylenesorbitan monolaurate, BDH, Poole, UK)]
on a platform shaker for 1 h at room temperature. Then the membrane was
washed three times (5 min each) with PBS-Tween 0.1% and then incubated
in primary antibody at a concentration according to antibody manufacturer
(usually 1:500–1:1000) in 3% BSA (Sigma-Aldrich) overnight at 4°C. The
membrane was washed three times in PBS-Tween 0.1% prior to incubation
with a secondary antibody, linked to horseradish peroxidase at a
concentration of 1:10,000 in 5% dried skimmed milk for 1 h. A final
series of washes was performed as above, before the blot was developed.
Nitrocellulose membrane was exposed for 1 min to the enhanced
chemiluminescence solution (ECL; Amersham) following the
manufacturer’s instructions. Excess ECL substrate was removed from the
membrane by touching the edge of the membrane to a piece of tissue paper.
Then the membrane was placed down on a film layer, which had been
arranged inside a film cassette. The bubbles were carefully removed from the
membrane, which was then covered with another film layer, fixed onto the
cassette with tape and exposed to photographic film (BioMax XAR Film
Kodak, Sigma-Aldrich) for an adequate exposure time. The film was
developed and immunoreactivity (band density) was quantified by using
densitometry (online source: http://rsbweb.nih.gov/ij/docs/user-guide.pdf )
using ImageJ.
Defining the whole embryo and cardiac phenotype
Whole embryo and cardiac phenotype following treatments and following
rescue were described on the basis of morphologic and functional
characteristics under bright-field microscopy. The embryo phenotype was
assessed using a simple six point scoring system – one point was allocated
for each of the following features: normal heart rate, normal head shape
and size, normal body axis, normal tail blood flow, absence of pericardial
oedema and absence of blood pooling. If these were all normal in any
single embryo, then this animal was scored as 6. Further detailed
phenotype characterisation was undertaken independently within our
laboratory for each of the three Cdk9 manipulations. In addition to the
above characteristics, this assessment also included body angle as a
measure of developmental stage, where 0–5% was considered normal,
curved was 5–50% and marked curvature was >50%. At least four
different clutches of larvae were assessed under each of the treatment
groups.
Statistical analysis
Experiments were performed in triplicate with, on average, 20–30 larvae per
experiment, unless otherwise stated. Data are presented as mean±s.e.m.
Statistical analyses were performed using GraphPad Prism 5. One-way or
two-way repeated measures ANOVA followed by Bonferroni post-hoc test
were used to compare means within and between groups. P-values <0.05
were considered significant.
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